Aptar Pharma, a US-based provider of dispensing solutions to the pharmaceutical industry, will expand its manufacturing facility in Congers, New York, to address the increasing demand for proprietary drug delivery systems from prescription and consumer healthcare customers in North America. The enhancement in manufacturing capabilities will include the implementation of new technologies, digitalisation, and cleanroom environments to align with market standards. The facility expansion was announced in March 2024 and is scheduled for launch in the fourth quarter of 2024.
It will be fully operational by early 2025. Details of Aptar Pharma’s global expansion plan The expansion of the Congers facility in North America is part of Aptar Pharma’s broader global injectables expansion programme, announced in 2020, to substantially increase capacity across multiple product lines within Aptar Pharma. The global expansion plan includes an injectables expansion programme in France and new manufacturing sites in Suzhou, China; and , India.
The Congers site expansion supports Aptar’s “local for local” approach, addressing the sustained customer demand in the region. The expansion is designed to continue to meet the growing needs of the customers in the region, which will ultimately benefit patients. Aptar Pharma manufacturing facility expansion details The new capacity will be accommodated within the building extension at the current Aptar Congers site.
The expansion will add 28,50.